In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.
The comparative in vitro activity of RU 64004 (also known as HMR 3004), a new ketolide antibiotic, was tested by agar dilution against approximately 500 gram-positive organisms, including multiply resistant enterococci, streptococci, and staphylococci. All streptococci were inhibited by < or = 1 microg of RU 64004 per ml. The ketolide was more potent than other macrolides against erythromycin A-susceptible staphylococci and was generally more potent than clindamycin against erythromycin A-resistant strains susceptible to this agent. Clindamycin-resistant staphylococci (MIC, > 128 microg/ml) proved resistant to the ketolide, but some erythromycin A- and clindamycin-resistant enterococci remained susceptible to RU 64004.
Schülin
T
T
Department of Medicine, Beth Israel-Deaconess Medical Center, Boston, Massachusetts 02215, USA.
Wennersten
C B
CB
Moellering
R C
RC
Eliopoulos
G M
GM
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002981:Clindamycin / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000494:pharmacology; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D048628:Ketolides; D018942:Macrolides; D008826:Microbial Sensitivity Tests / Q000379:methods
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C105420:RU 64004; D002981:Clindamycin; D004917:Erythromycin